2025
Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma: An Academic Gastrointestinal Cancer Consortium (AGICC) Study
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma: An Academic Gastrointestinal Cancer Consortium (AGICC) Study. The Oncologist 2025, oyaf271. PMID: 40972532, DOI: 10.1093/oncolo/oyaf271.Peer-Reviewed Original ResearchBR-PDAC patientsStereotactic body radiotherapyBR-PDACR-PDACNeoadjuvant therapyR0 resectionSurgical resectionOverall survivalResection rateSingle arm phase 2 studyBorderline resectable pancreatic adenocarcinomaBorderline resectable PDACLocalized Pancreatic CancerResectable pancreatic adenocarcinomaSurgical resection rateR0 resection rateResidual microscopic diseasePhase 2 studyMedian OSGemcitabine/nab-paclitaxelPerioperative therapyResectable PDACMicroscopic diseaseOptimal regimenPrimary endpointEvaluating Variation in Lymph Node Sampling During Sentinel Lymph Node Biopsy for Melanoma
Taylor C, Niba V, Baskin A, Mott N, Kim E, Kappelman A, Wang T, Sinco B, Francescatti A, Boffa D, Hendren S, Boughey J, Hieken T, Weigel R, Hughes T, Dossett L. Evaluating Variation in Lymph Node Sampling During Sentinel Lymph Node Biopsy for Melanoma. Annals Of Surgical Oncology 2025, 1-8. PMID: 40819148, DOI: 10.1245/s10434-025-18063-5.Peer-Reviewed Original ResearchSentinel lymph node biopsyLymph node biopsyNodal yieldNode biopsyMedian nodal yieldNational Cancer DatabaseManagement of melanomaLymph node samplingUpper extremityNodal positivityNodal surgeryNeoadjuvant therapyNodal stagingMelanoma patientsCommission on CancerCancer DatabaseBreast cancerFacility-level variationMargin widthNode samplingMelanomaExcision depthPatientsLogistic regressionBiopsyTiming of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer
Licata L, Mariani M, Viale G, Dent R, Tolaney S, Schmid P, Hamilton E, Sotiriou C, Pusztai L, Bianchini G. Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research 2025, 31: 3916-3921. PMID: 40689866, PMCID: PMC12434393, DOI: 10.1158/1078-0432.ccr-25-1478.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNeoadjuvant chemo-immunotherapyEarly-stage triple-negative breast cancerChemo-ImmunotherapyTime of recurrenceClinical trialsEarly recurrenceBreast cancerMetastatic triple-negative breast cancerPathological complete response statusHigh-risk triple-negative breast cancerEvent-free survival dataPathological complete responseRisk of relapseRisk of recurrenceKaplan-Meier curvesOverall riskImmunotherapy armKEYNOTE-522Neoadjuvant therapyComplete responseResidual diseaseEarly relapsePrimary endpointOptimal therapyImmune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
Wolf D, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, Investigators I, Symmans W, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin E, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van ‘t Veer L, Mukhtar R, Melisko M, Wallace A, Yeung K, Albain K, Robinson P, Lo S, Olopade F, Potter D, Beckwith H, Blaes A, Boughey J, Haddad T, Elias A, Isaacs C, Mitri Z, Kemmer K, Lu J, Lang J, Thomas A, Trivedi M, Hershman D, Meisel J, Kalinsky K, Vaklavas C, Williams N, Ellis E, Sanford A, Sanft T, Viscusi R, Arora M, Falkson C, Northfelt D, Murthy R, Haley B, Yung R, Mayer I, Khan Q, Edmiston K. Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precision Oncology 2025, 9: e2400776. PMID: 40526879, PMCID: PMC12184982, DOI: 10.1200/po-24-00776.Peer-Reviewed Original ResearchConceptsPCR ratePredicting pathologic complete responseTriple-negative breast cancerNeoadjuvant immunotherapyTumor gradeHormone receptor-positive early-stage breast cancerHuman epidermal growth factor receptor 2-negativeBreast cancerEarly-stage triple-negative breast cancerImmune-related adverse eventsControl armEarly-stage breast cancerMammaPrint-high riskHormone receptor-positivePathological complete responseResponse to IOI-SPY2 trialStandard of careER-lowComplete responseNeoadjuvant therapyReceptor-positiveHER2+I-SPY2Adverse eventsA composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Hennessy M, Cimino-Mathews A, Carter J, Kachergus J, Ma Y, Leal J, Solnes L, Abramson V, Carey L, Rimawi M, Specht J, Storniolo A, Vaklavas C, Krop I, Winer E, Denbow R, Valero V, Wolff A, Wahl R, Huang C, Stearns V, Thompson E, Connolly R. A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). The Breast 2025, 81: 104432. PMID: 40049115, PMCID: PMC11928837, DOI: 10.1016/j.breast.2025.104432.Peer-Reviewed Original ResearchTissue-based biomarkersBreast cancerHER2-positive breast cancerHER2 3+Negative predictive valueEarly metabolic changesNeoadjuvant pertuzumabScore cut-offNeoadjuvant therapyIntrinsic subtypesSULmaxC1D15PET/CTDays post-initiationHER2 proteinYouden indexComposite biomarkerDe-intensificationHER2Post-initiationPredictive valueBiomarker performanceC-statisticImaging biomarkersMetabolic changesOutcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population.
Ganguly A, Paladiya R, Ingawale S, Giri S, Abbagoni V, Thumar J. Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population. Journal Of Clinical Oncology 2025, 43: 208-208. DOI: 10.1200/jco.2025.43.4_suppl.208.Peer-Reviewed Original ResearchTNT groupTotal neoadjuvant therapyLocally Advanced Rectal CancerAdvanced rectal cancerManagement of locally advanced rectal cancerTumor locationNeoadjuvant therapyConventional therapyRectal cancerCT groupPropensity score matchingLow tumorsHigh tumorNo responsePathologic response to treatmentTreating locally advanced rectal cancerResponse ratePartial response ratePathological response rateScore matchingFisher's exact testResponse to treatmentComplete responseAdjuvant treatmentUnderserved populationsIdentifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study. Journal Of Clinical Oncology 2025, 43: 275-275. DOI: 10.1200/jco.2025.43.4_suppl.275.Peer-Reviewed Original ResearchMolecular residual diseaseColorectal cancerCtDNA detectionDetection of molecular residual diseaseWeek 8Week 4Resectable colorectal cancerYear of surgeryTime of surgerySingle nucleotide variantsYear Follow-UpPost-surgical timesNeoadjuvant therapyResidual diseaseCurative intentMRD assaysResidual cancerClinical relapseDisease recurrenceCtDNA concentrationRecurrent cancerClinical outcomesCfDNA concentrationFollow-upRecurrence
2024
Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma
Dunne E, Fick C, Mastrogiacomo B, Tan K, Toumbacaris N, Vanstraelen S, Rocco G, Chaft J, Iyengar P, Gomez D, Adusumilli P, Park B, Isbell J, Bott M, Sihag S, Molena D, Huang J, Jones D. Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma. JTCVS Open 2024, 22: 458-469. PMID: 39780816, PMCID: PMC11704575, DOI: 10.1016/j.xjon.2024.09.030.Peer-Reviewed Original ResearchResection of lung adenocarcinomaMaximum standardized uptake valueDevelopment of brain metastasesBrain metastasesStandardized uptake valueNeoadjuvant therapyLung adenocarcinomaAssociated with developmentLymphovascular invasionTP53 mutationsUptake valueCumulative incidence of brain metastasesMarker of aggressive tumor biologyHighest maximum standardized uptake valueLack of extracranial metastasesIncidence of brain metastasesNext-generation sequencingPanel next-generation sequencingAssociated with better survivalStage III diseaseMedian Follow-UpAggressive tumor biologyBetter performance statusAssociated with brain metastasisStereotactic radiosurgeryOverall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Im S, Untch M, Fasching P, Mouret-Reynier M, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. New England Journal Of Medicine 2024, 391: 1981-1991. PMID: 39282906, DOI: 10.1056/nejmoa2409932.Peer-Reviewed Original ResearchEarly-stage triple-negative breast cancerTriple-negative breast cancerPembrolizumab-chemotherapy groupPlacebo-chemotherapy groupCycles of pembrolizumabPathological complete responseEvent-free survivalOverall survivalBreast cancerAdjuvant pembrolizumabComplete responseSafety profile of pembrolizumabData cutoff dateUntreated stage IIPlatinum-containing chemotherapyMedian Follow-UpEstimate overall survivalSecondary end pointsEpirubicin-cyclophosphamideNeoadjuvant pembrolizumabNeoadjuvant therapyDoxorubicin-cyclophosphamideNeoadjuvant chemotherapyDefinitive surgeryPembrolizumabNCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.
Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Jones F, Gurski L. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: 366-375. PMID: 39151454, DOI: 10.6004/jnccn.2024.0041.Peer-Reviewed Original ResearchConceptsRectal cancerResponders to neoadjuvant therapyRisk of pelvic recurrenceLocally recurrent rectal cancerEarly-stage rectal cancerNonoperative management approachRecurrent rectal cancerDistal rectal cancerNCCN Guidelines InsightsCurative-intent therapyRectal cancer surgeryOptimal treatment planEndoscopic submucosal dissectionQuality of lifePelvic recurrenceNeoadjuvant therapyMultimodal therapyNCCN guidelinesGenitourinary functionPatient selectionPoor prognosisCancer surgeryColon cancerSubmucosal dissectionClinical trialsTailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations
Elghazaly H, Azim H, Rugo H, Cameron D, Swain S, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, Saghir N, Penault‐Llorca F, Perez E, Poortmans P, Abdelaziz H, El‐Zawahry H, Kassem L, Sabry M, Viale G, Al‐Sukhun S, Gado N, Leung J, Elarab L, Cardoso M, Karim K, Foheidi M, Elmaadawy M, Conte P, Selim A, Kandil A, Kamal R, Paltuev R, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel‐Aziz A, Eldin N. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer 2024, 130: 3251-3271. PMID: 38985794, DOI: 10.1002/cncr.35389.Peer-Reviewed Original ResearchBreast cancerNeoadjuvant therapyManagement of early breast cancerEarly breast cancerIndividual patient managementDe-escalation strategiesModified Delphi approachBC expertsPostneoadjuvant treatmentSystemic therapyClinical evidencePatient managementConsensus recommendationsClinical situationsTherapyDe-EscalationDelphi approachTherapy outcomeTreatment settingsCancerExpert opinionRecommendationsBreastConsensusLate recurrence of completely resected stage I to IIIA lung adenocarcinoma
Fick C, Dunne E, Toumbacaris N, Tan K, Mastrogiacomo B, Park B, Adusumilli P, Molena D, Gray K, Sihag S, Huang J, Bott M, Rocco G, Isbell J, Jones D. Late recurrence of completely resected stage I to IIIA lung adenocarcinoma. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: 445-453.e3. PMID: 38950771, PMCID: PMC11682191, DOI: 10.1016/j.jtcvs.2024.06.026.Peer-Reviewed Original ResearchAggressive pathological featuresLate recurrenceLung adenocarcinomaFollow-upPathological featuresAssociated with late recurrenceElevated risk of recurrenceFactors associated with late recurrenceRetrospective analysis of patientsRecurrence of lung adenocarcinomaHistory of lung cancerStage IIIA diseaseTime of resectionRisk of recurrenceAnalysis of patientsGenomic mutationsNeoadjuvant therapyIIIA diseaseEarly recurrenceClinicopathological variablesLogistic regression modelsRetrospective analysisLung cancerRecurrencePatientsPredicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer.
Feiger B, Biancalana M, Shelton A, Blenman K, Lustberg M. Predicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer. Journal Of Clinical Oncology 2024, 42: e12639-e12639. DOI: 10.1200/jco.2024.42.16_suppl.e12639.Peer-Reviewed Original ResearchBreast cancer patientsNeoadjuvant chemotherapyPeripheral neuropathyNeoadjuvant therapyBreast cancerCancer patientsAdministration of neoadjuvant chemotherapyCohort of breast cancer patientsLikelihood of breast-conserving surgeryContrast-enhanced magnetic resonance imagingQuality of lifeDynamic contrast-enhanced magnetic resonance imagingBreast-conserving surgeryReduced tumor burdenTreatment-induced neuropathyOccurrence of neuropathyInduce peripheral neuropathyDensity of blood vesselsPatients' quality of lifeMagnetic resonance imagingAmeliorate neuropathyDCE-MRI dataTumor burdenCumulative toxic effectsIntratumoral vascularityPerioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. Journal Of Clinical Oncology 2024, 42: 4175-4175. DOI: 10.1200/jco.2024.42.16_suppl.4175.Peer-Reviewed Original ResearchR0 resection rateBR-PDACR0 resectionNeoadjuvant therapyR-PDACResection ratePancreatic adenocarcinomaOverall survivalResected tumorAdverse eventsImproved R0 resection ratesNon-hematological adverse eventsBorderline resectable pancreatic adenocarcinomaPhase 2 clinical trialBorderline resectable tumorsBR-PDAC patientsCentral radiology reviewLocalized pancreatic adenocarcinomaMulticenter open-labelCycles of gemcitabineResectable pancreatic adenocarcinomaStereotactic radiation therapyComplete surgical resectionHematologic AENab-paclitaxelNeoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis
Johnson B, Teply B, Kagemann C, McGuire B, Lombardo K, Jing Y, Langbo W, Epstein J, Netto G, Baras A, Matoso A, McConkey D, Gupta A, Ahuja N, Ross A, Pierorazio P, Comperat E, Hoffman-Censits J, Singla N, Patel S, Kates M, Choi W, Bivalacqua T, Hahn N. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis. Bladder Cancer 2024, 10: 133-143. PMID: 39131872, PMCID: PMC11308648, DOI: 10.3233/blc-240008.Peer-Reviewed Original ResearchExpression of immune checkpointsClinical activityNeoadjuvant cisplatinImmune checkpointsT cellsIncreased expression of immune checkpointsTranscriptome RNA sequencingMuscle-invasive patientsPegfilgrastim 6 mgAggressive histologic subtypePathological complete responseUrothelial bladder cancerT cell genesBasal-squamousYpCR rateNeoadjuvant therapyComplete responseHistological subtypesSingle-institutionUrothelial cancerPrimary endpointUrothelial tumorsTumor biologyBladder cancerGrade 3Factors Associated With Racial and Ethnic Disparities in Locally Advanced Rectal Cancer Outcomes
Shulman R, Deng M, Handorf E, Meyer J, Lynch S, Arora S. Factors Associated With Racial and Ethnic Disparities in Locally Advanced Rectal Cancer Outcomes. JAMA Network Open 2024, 7: e240044. PMID: 38421650, PMCID: PMC10905315, DOI: 10.1001/jamanetworkopen.2024.0044.Peer-Reviewed Original ResearchConceptsPathological complete responseLocally Advanced Rectal CancerSocial determinants of healthRate of pathological complete responseNon-Hispanic black patientsNon-Hispanic white patientsDeterminants of healthNational Cancer DatabaseNeoadjuvant therapyPN0 statusTumor downstagingSocial determinantsEthnic disparitiesRectal cancerCancer DatabaseRates of tumor downstagingWhite patientsLymph node-positive diseaseNon-Hispanic black raceTreatment outcomesBlack patientsAssociated with treatment responseNon-Hispanic blacksNon-Hispanic whitesNode-positive diseaseNeoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Albain K, Yau C, Petricoin E, Wolf D, Lang J, Chien A, Haddad T, Forero-Torres A, Wallace A, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias A, Clark A, Godellas C, Boughey J, Isaacs C, Tripathy D, Lu J, Yung R, Gallagher R, Wulfkuhle J, Brown-Swigart L, Krings G, Chen Y, Potter D, Stringer-Reasor E, Blair S, Asare S, Wilson A, Hirst G, Singhrao R, Buxton M, Clennell J, Sanil A, Berry S, Asare A, Matthews J, DeMichele A, Hylton N, Melisko M, Perlmutter J, Rugo H, Symmans W, Van't Veer L, Yee D, Berry D, Esserman L. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clinical Cancer Research 2024, 30: 729-740. PMID: 38109213, PMCID: PMC10956403, DOI: 10.1158/1078-0432.ccr-22-2256.Peer-Reviewed Original ResearchPathological complete responseI-SPY2Breast cancerStage II/III breast cancerPhase II neoadjuvant trialTie2 receptorEarly-stage breast cancerT-cell gene signatureHormone receptorsDoxorubicin/cyclophosphamideHER2-negative diseaseHER2-positive diseaseStandard neoadjuvant therapyEvent-free survivalPhase III trialsPaclitaxel-based chemotherapyBreast cancer trialsPathway-specific biomarkersCell gene signatureNeoadjuvant trialsWeekly paclitaxelNeoadjuvant therapyPrimary endpointIII trialsPCR rateTROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy
Bardia A, Pusztai L, Albain K, Ciruelos E, Im S, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances In Medical Oncology 2024, 16: 17588359241248336. PMID: 38686016, PMCID: PMC11057345, DOI: 10.1177/17588359241248336.Peer-Reviewed Original ResearchInvasive disease-free survivalResidual invasive diseasePathological complete responseTriple-negative breast cancerDisease-free survivalNeoadjuvant therapyInvasive diseaseSurgical resectionBreast cancerHigh risk of disease recurrenceTopoisomerase I inhibitor payloadRisk of disease recurrenceStandard-of-care therapyAdjuvant treatment approachesPhase III studyTreatment of patientsWritten Informed ConsentAntibody-drug conjugatesAged 18-yearsComplete responseNeoadjuvant treatmentInstitutional review boardOverall survivalDisease recurrenceIII studiesTBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
Lynce F, Stevens L, Li Z, Brock J, Gulvady A, Huang Y, Nakhlis F, Patel A, Force J, Haddad T, Ueno N, Stearns V, Wolff A, Clark A, Bellon J, Richardson E, Balko J, Krop I, Winer E, Lange P, Hwang E, King T, Tolaney S, Thompson A, Gupta G, Mittendorf E, Regan M, Overmoyer B, Polyak K. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Research 2024, 26: 20. PMID: 38297352, PMCID: PMC10829369, DOI: 10.1186/s13058-024-01774-0.Peer-Reviewed Original ResearchConceptsInflammatory breast cancerPathological complete responseTriple-negative IBCPhase II studyTN-IBCIL-6/JAK/STAT3 signalingBreast cancerRandomized phase II studyRun-inInvestigation of novel therapiesDoxorubicin plus cyclophosphamideTreatment naive patientsImmune suppressive effectsGrowth inhibitory effectNeoadjuvant therapyPreoperative therapyComplete responsePhosphorylated STAT3Tumor biopsiesWorse survivalII studyPrimary endpointSecondary endpointsImmune suppressionT cells
2023
The Predictors of Complete Pathologic Response in Rectal Cancer during the Total Neoadjuvant Therapy Era: A Systematic Review
Flom E, Schultz K, Pantel H, Leeds I. The Predictors of Complete Pathologic Response in Rectal Cancer during the Total Neoadjuvant Therapy Era: A Systematic Review. Cancers 2023, 15: 5853. PMID: 38136397, PMCID: PMC10742121, DOI: 10.3390/cancers15245853.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTotal neoadjuvant therapyPathologic complete responseClinical complete responseNeoadjuvant therapyComplete responseSystematic reviewRectal cancerTumor responseClinical stage 2Complete pathologic responseRetrospective cohort studyRandomized clinical trialsHeterogeneity of studiesLevel of evidenceElectronic databases EmbaseIdentification of predictorsCancer treatment paradigmLong-term trialsNeoadjuvant chemotherapyTherapy eraPatient demographicsPreoperative predictorsClinical factorsClinicopathologic factorsCohort study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply